$TGTX - correct it’s what many investors miss with $TGTX BRIUMVI especially the critics - DURATION of BRIUMVI likely over 10 years + Reoccurring Revenue just starting to compound here - all ready being Profitable here - continues to be nice longterm setup going forward

$AXSM Another excellent Qtr(Q2,2024) highlighted by the long awaited capitulation of the last Maj.Brokerage detractor, BofA(Buy, $106),marks, universal acknowledgment of this large,expanding CNS program,& effective “Last man standing”status in post SSRI MDD Tx. Sweet😀! $XBI $IBB

$tgtx pullback surprising & not at same time. People pushing off taxes selling in 2025. Vol bout 800k so not huge. If I’m MM , wud not step in until I c selling over. Not seeing material option action

$AXSM pipeline from the 10k. The company could have 5 approved products soon.

Great $AXSM vibes today…Are we setting up for positive ADHD Rs, or, +Solriamfetol Rs in MDD, or both😍…Guess we’ll know soon enough!:-) $XBI $IBB

$AXSM Weekly Revs? Another nice week of increases! And a beautiful chart, confirming the long-standing trend! $XBI $IBB

Bottom of the 9th, Game 7 of the World Series. Bases loaded, 2 outs, and your team is down by 1 Mariano Rivera is on the mound. You have your choice of any hitter, of any era. Who gets the call?

$AXSM key pipeline asset, Auvelity for ADA, company narrowed its guidance for sNDA submission timing (now 3Q from 2H25 BofA ADA opportunity comprises ~30% of our total Axsome valuation and we believe it represents a meaningful label expansion opportunity

cnbc.com/video/2025/05/…

$ASXM - light volume - reduced short interest - feeling like the company is positioned well in all respects. Good time to dip in if you haven't already.

Despite competitive anxiety concerning alternative risk investment ops(AI, crypto, biotech, energy, etc.), Oppenheimer’s new post R&D day report($AXSM PT $183) does a good job of summarizing the ever growing multi drug CNS investment thesis for $AXSM $XBI $IBB

$TGTX / $AXSM Great earnings .. I am a buyer

$TGTX 🦉State Street Corp disclosed a 5.1% stake in TG Therapeutics, holding 8.1M shares with shared voting and disposal power. Filing signed Nov 7 2025. #form_SCHEDULE_13G ir.tgtherapeutics.com/static-files/2…